TY - JOUR
T1 - Physical function impairment and frailty in middle-aged people living with human immunodeficiency virus in the REPRIEVE trial ancillary study PREPARE
AU - ACTG A5361S (PREPARE) Team
AU - Umbleja, Triin
AU - Brown, Todd T.
AU - Overton, Edgar T.
AU - Ribaudo, Heather J.
AU - Schrack, Jennifer A.
AU - Fitch, Kathleen V.
AU - Douglas, Pamela S.
AU - Grinspoon, Steven K.
AU - Henn, Sarah
AU - Arduino, Roberto C.
AU - Rodriguez, Benigno
AU - Benson, Constance A.
AU - Erlandson, Kristine M.
N1 - Funding Information:
This work was supported by the NIA (grant R01AG 054366), the NHLBI (grants U01 HL123336 and U01 HL123339), and the NIAID (UM1 AI068636 and UM1 AI106701).
Publisher Copyright:
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - Background. People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, hospitalizations, and death. Identifying factors associated with physical function impairment and frailty can help target interventions. Methods. The REPRIEVE trial enrolled participants 40-75 years of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with low to moderate cardiovascular disease risk. We conducted a cross-sectional analysis of those concurrently enrolled in the ancillary study PREPARE at enrollment. Results. Among the 266 participants, the median age was 51 years; 81% were male, and 45% were black, and 28% had hypertension. Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 25 to <30 in 38% and ≥30 in 30%, 33% had a high waist circumference, 89% were physically inactive, 37% (95% confidence interval, 31%, 43%) had physical function impairment (Short Physical Performance Battery score ≤10), and 6% (4%, 9%) were frail and 42% prefrail. In the adjusted analyses, older age, black race, greater BMI, and physical inactivity were associated with physical function impairment; depression and hypertension were associated with frailty or prefrailty. Conclusions. Physical function impairment was common among middle-aged PWH; greater BMI and physical inactivity are important modifiable factors that may prevent further decline in physical function with aging.
AB - Background. People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, hospitalizations, and death. Identifying factors associated with physical function impairment and frailty can help target interventions. Methods. The REPRIEVE trial enrolled participants 40-75 years of age, receiving stable antiretroviral therapy with CD4+ T-cell count >100 cells/mm3, and with low to moderate cardiovascular disease risk. We conducted a cross-sectional analysis of those concurrently enrolled in the ancillary study PREPARE at enrollment. Results. Among the 266 participants, the median age was 51 years; 81% were male, and 45% were black, and 28% had hypertension. Body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) was 25 to <30 in 38% and ≥30 in 30%, 33% had a high waist circumference, 89% were physically inactive, 37% (95% confidence interval, 31%, 43%) had physical function impairment (Short Physical Performance Battery score ≤10), and 6% (4%, 9%) were frail and 42% prefrail. In the adjusted analyses, older age, black race, greater BMI, and physical inactivity were associated with physical function impairment; depression and hypertension were associated with frailty or prefrailty. Conclusions. Physical function impairment was common among middle-aged PWH; greater BMI and physical inactivity are important modifiable factors that may prevent further decline in physical function with aging.
KW - Aging
KW - Frailty
KW - HIV
KW - Physical function
KW - SPPB
UR - http://www.scopus.com/inward/record.url?scp=85087838441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087838441&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiaa249
DO - 10.1093/infdis/jiaa249
M3 - Article
C2 - 32645163
AN - SCOPUS:85087838441
SN - 0022-1899
VL - 222
SP - S52-S62
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - Supplement_1
ER -